Psychiatric Disease Mouse Model Development Services

Creative Biolabs provides custom psychiatric disease mouse model development services for researchers investigating disease mechanisms, validating therapeutic targets, or evaluating experimental compounds. We help select and qualify genetic, pharmacological, environmental, or combined models, define relevant behavioral endpoints, and connect those endpoints with molecular, physiological, or circuit-level evidence.

Our expertise extends across a spectrum of psychiatric conditions, enabling us to develop and validate models tailored to the unique characteristics of each disorder.

• Schizophrenia Mouse Model Development
• Autism Spectrum Disorder Mouse Model Development
• Depression Mouse Model Development
• Anxiety Mouse Model Development
• Attention-Deficit/Hyperactivity Disorder Mouse Model Development

Define the Behavioral and Biological Question

Psychiatric model selection begins with the function or mechanism the study must explain. Reduced reward preference, altered avoidance, impaired sensorimotor gating, and reduced social exploration can arise through different pathways and occur across diagnostic categories. We identify the intended experimental domain, the proposed cause of the phenotype, and the evidence required to support a model-specific conclusion before choosing an induction method or assay battery.

• Research objective: Distinguish exploratory disease biology, genetic target validation, assay development, and candidate efficacy testing.
• Phenotype of interest: Define the behavioral or physiological change that matters, including its expected direction, onset, persistence, and relevance to the target mechanism.
• Model rationale: Choose a genetic alteration, environmental exposure, developmental context, pharmacological challenge, or justified combination that can address the hypothesis.
• Comparator strategy: Specify appropriate baseline, vehicle, littermate, exposure-matched, or reference-treatment controls.
• Decision criteria: Agree on the primary endpoint, supporting measures, tolerability requirements, and the level of replication needed before advancing a conclusion.

The resulting plan can connect with our Neurological Disease Modeling and Drug Efficacy Testing Service. Early consultation can determine whether an established model is sufficient or a feasibility phase is needed to establish a reproducible and intervention-sensitive window. Model complexity is increased only when it resolves an uncertainty relevant to the research decision.

Select a Model with a Clear Experimental Rationale

Genetic and environmental models answer different questions. A defined allele can test a mechanistic hypothesis, while an environmental paradigm can reveal susceptibility or adaptation within a particular biological context. Pharmacological challenges offer controlled perturbations of a pathway, but their acute effects should not be confused with the developmental course of a chronic disorder. We consider strain, background, age, sex, housing, and the test history alongside the nominal model name.

Depression and Stress Related Models

Depression-focused studies can compare reward-related behavior, social interaction, activity, and selected stress-system or synaptic measurements. The induction method follows the hypothesis rather than an expectation that every model will show every depression-associated endpoint. A social avoidance phenotype, for example, does not automatically imply reduced sucrose preference or a change in stress-coping behavior. Baseline differences and the persistence of the intended phenotype are established before drug testing.

Related options include Depression Mouse Model Development Services, Chronic Unpredictable Mild Stress Model Development Service, and Chronic Social Defeat Stress Model Development Service. A named stress paradigm is treated as a starting framework whose suitability still depends on the strain, cohort, housing, and endpoint.

Anxiety and Threat Related Models

Anxiety-focused programs can assess approach–avoidance behavior, responses to novelty, threat learning, or persistent stress-related changes. Different assays sample different aspects of behavior and are not interchangeable measures of a single internal state. We qualify both the primary behavior and the general capacity to perform the task. Reduced exploration may reflect avoidance, sedation, motor impairment, or altered sensory processing, and these alternatives guide the control panel.

Projects can draw on Stress induced Anxiety Mouse Model Development Service, Genetic Anxiety Mouse Model Development Service, or Pharmacological induced Anxiety Mouse Model Development Service. The selected strategy depends on whether the question concerns a persistent susceptibility state, a specific target, or an acute pharmacological response.

Schizophrenia Relevant Models

Schizophrenia-focused programs may investigate sensorimotor gating, working memory, flexibility, social exploration, or dopaminergic and glutamatergic mechanisms. Ketamine, PCP, and MK-801 perturb NMDA receptor signaling but differ in pharmacology and time course. Acute, repeated, and post-exposure measurements therefore require separate interpretation. Hyperlocomotion, a PPI change, or reduced social interaction supports a particular experimental observation rather than demonstrating hallucinations, delusions, or the full symptom spectrum of schizophrenia.

The Schizophrenia Mouse Model Development Services, MK-801 induced Schizophrenia Model Development Service, and Phencyclidine induced Schizophrenia Model Development Service provide related routes. Genetic or developmental approaches can be assessed when the study requires a persistent mechanism beyond the pharmacological challenge window.

Genetic Developmental and Cross Disorder Studies

Custom knockout, knock-in, conditional, or transgenic approaches can be considered for a defined target hypothesis, subject to feasibility and strain availability. Qualification includes allele identity, genetic background, breeding strategy, developmental effects, and baseline health. Conditional designs may help distinguish developmental from adult functions, but recombination efficiency and cell-type specificity need confirmation. A single risk-associated gene is not assumed to account for a complex psychiatric disorder.

Neurodevelopmental programs can connect with Autism Spectrum Disorder Mouse Model Development Services or Attention-Deficit/Hyperactivity Disorder Mouse Model Development Service. Social, repetitive, attention-related, and activity measures are selected as distinct domains. Behavioral differences are described operationally rather than as evidence that an animal has a human diagnosis.

Build a Behavioral Battery

A useful behavioral battery combines a prespecified primary endpoint with controls that address its most plausible alternative explanations. More tests do not automatically produce stronger evidence: repeated novelty, stress, learning, or habituation can change later performance. We plan test order, recovery intervals, and the need for independent cohorts before data collection. Video tracking and automated scoring are checked against task-specific definitions and blinded manual review where appropriate.

Separate Task Performance from Disease Relevant Behavior

An apparent anxiolytic response can reflect increased activity, while a reduction in challenge-induced locomotion can reflect sedation. Cognitive performance can change because an animal explores less, responds more slowly, or is less motivated to obtain a reward. We therefore interpret each primary endpoint alongside measures of task engagement and basic performance. A nonspecific performance change is not labeled therapeutic rescue simply because it moves a summary score toward a control value.

For PPI studies, baseline startle amplitude and sensory function are considered because gating calculations can be unstable when the underlying startle response is small or substantially altered. For social tests, olfactory cues and familiarity influence interaction. For sucrose preference, total fluid intake and metabolic or taste-related effects may change the result. These controls are chosen for the candidate mechanism and the model rather than applied as a generic checklist.

Use Precise Language for Stress and Coping Measures

Immobility in forced-swim or tail-suspension tasks is interpreted as a task-specific coping response under the tested conditions, not as a direct measure of sadness, hopelessness, or suicidal behavior. Such measures, when justified, are considered with activity and other relevant outcomes rather than used as a standalone diagnosis. Similarly, reduced center time in an open field is evaluated alongside total movement and environmental conditions before an anxiety-related interpretation is made.

Susceptible and resilient classifications are defined prospectively for the chosen metric, with thresholds and handling of borderline values specified before analysis. A mouse classified by social interaction may remain unaltered on another endpoint. If animals are selected into subgroups using a baseline behavioral score, subsequent analyses account for that selection and avoid treating the defining metric as independent proof of a broad disease state.

Connect Behavior with Biological Mechanisms

Mechanistic modules can help explain why a model or treatment changes behavior. The panel follows the candidate target and the relevant brain region rather than measuring broad marker lists without a hypothesis. Possible endpoints include target expression or engagement, selected neurotransmitters and metabolites, stress-axis signaling, synaptic proteins, cell-type markers, inflammatory mediators, and electrophysiological properties. Specialized technologies are assessed for feasibility during scoping.

• Neurotransmitter and signaling pathways: Evaluate selected dopaminergic, glutamatergic, GABAergic, serotonergic, or intracellular signaling endpoints when they are relevant to the intervention.
• Stress-system physiology: Consider corticosterone and related measures with sampling time, handling, circadian state, and recent behavior documented.
• Synaptic and cellular biology: Examine region-specific synaptic, neuronal, or glial endpoints with appropriate anatomical and assay controls.
• Circuit and functional measurements: Add qualified electrophysiology or other functional analyses when these can test a causal hypothesis beyond descriptive behavior.
• Discovery profiling: Use transcriptomic, proteomic, or other exploratory analyses with a clear comparison, appropriate biological replication, and a plan for independent confirmation.

Association does not establish mediation. A cytokine, synaptic marker, or neurotransmitter-related measurement that changes alongside behavior may reflect the challenge, treatment, or recent testing. Stronger mechanistic evidence may require temporal sampling, target perturbation, a regional comparison, or an independent cohort. Terminal tissue collection is planned around exposure and the behavior window so that the biological measurements can support the intended interpretation.

Related Research

Social Stress Studies Reveal Endpoint Specific Protocol Effects

Shoji and Miyakawa compared procedural variants of a social defeat stress paradigm in male mice. Housing and exposure conditions influenced selected behavioral outcomes, while susceptibility classification and other endpoints did not change uniformly. The selected open-field panels illustrate why movement and center exploration should be evaluated together. For service design, the study supports documenting housing and test conditions and qualifying the exact outcome required, rather than assuming that a named stress model produces a fixed behavioral syndrome. The findings also do not justify increasing stress burden simply to obtain a larger effect.

Fig. 1 Open-field distance and center time under the published post-defeat housing conditions.^1,3

A Pharmacological Model Can Support a Defined Neurochemical Readout

Petty and colleagues used fluorodopa PET analysis to assess dopamine synthesis-related measures in a sub-chronic ketamine mouse model. They reported increased midbrain uptake-derived synthesis capacity and examined its relationship with the striatal measurement. The figure illustrates a biological readout linked to a particular model mechanism, complementing behavioral characterization.

Fig. 2 Midbrain dopamine synthesis-related PET measurements and striatum–midbrain relationships in the published ketamine model.^2,3

Frequently Asked Questions

1. What do psychiatric disease mouse model development services include?

   Projects can include model selection or development, cohort and control planning, phenotype qualification, behavioral testing, mechanism assays, and candidate efficacy studies. The scope is defined around a measurable research question, the model's biological rationale, and the development decision the data must support.

2. Which psychiatric research areas can the service support?

   Studies can address depression- and anxiety-related domains, schizophrenia-relevant phenotypes, stress susceptibility and resilience, and selected neurodevelopmental or cross-disorder questions. Genetic, pharmacological, environmental, and combined approaches are assessed for suitability and availability rather than treated as interchangeable models.

3. How do you choose between genetic and induced models?

   A genetic model can test a defined target or developmental mechanism, while an environmental or pharmacological model can examine responses to a controlled exposure. We consider phenotype persistence, strain, sex, age, controls, and the intended treatment window when selecting the approach.

4. Can behavioral results be separated from sedation or motor impairment?

   Studies can pair the primary endpoint with activity, motor, sensory, health, and task-engagement measures selected for the assay and compound. PPI studies consider baseline startle and hearing, while social and reward tasks may need olfactory, intake, or motivation-related controls.

5. Do you use a fixed behavioral battery for every model?

   No. The battery follows the research question and model phenotype. We select a primary endpoint and supporting controls, plan test order and recovery, and consider separate cohorts when earlier tasks could alter later behavior. Additional assays are added when they resolve a relevant uncertainty.

6. Can molecular or functional endpoints accompany behavioral testing?

   Yes, subject to feasibility. Studies can incorporate target engagement, selected neurotransmitter or stress-system measures, region-specific molecular analysis, synaptic or glial endpoints, and qualified functional studies. Sampling time and tissue selection are aligned with exposure and the behavioral question.

7. Can the service evaluate candidate drug efficacy?

   Qualified models can support preventive, concurrent, or rescue treatment studies with matched controls, appropriate reference treatments, dose-response analysis, and tolerability assessment. Exposure and target engagement can be added where feasible. Results support a model-specific preclinical conclusion rather than a guarantee of clinical efficacy.

8. What information is useful when starting a project?

   Useful inputs include the target mechanism, intended behavioral domain, preferred model or genotype, strain and sex considerations, candidate properties, treatment objective, required biological endpoints, and advancement criteria. A feasibility phase can establish the phenotype and assay window when these parameters remain open.

References

1. Shoji, Hirotaka, and Tsuyoshi Miyakawa. "Comparative Analysis of Procedural Variations in the Social Defeat Stress Paradigm in Mice: Effects of Post-Defeat Housing Conditions and Aggressor Exposure Duration." Molecular Brain, vol. 19, 2026, article 53. https://doi.org/10.1186/s13041-026-01325-y
2. Petty, Alice, et al. "Sub-Chronic Ketamine Administration Increases Dopamine Synthesis Capacity in the Mouse Midbrain: A Preclinical In Vivo PET Study." Molecular Imaging and Biology, vol. 25, 2023, pp. 1054-62. https://doi.org/10.1007/s11307-023-01865-y
3. Distributed under Open Access license CC BY 4.0, without modification.